NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02870920,Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT02870920,,COMPLETED,"The standard or usual treatment for this disease is treatment with drugs and other treatments that may help to make a patient better or may improve their quality of life. This treatment is known as ""best supportive care"" (BSC). Although patients with best supportive care can feel better for some months, the cancer usually continues to grow.",YES,Colorectal Cancer,DRUG: Tremelimumab|DRUG: Durvalumab|OTHER: Best Supportive Care,"Overall Survival, Time from randomization to death from any cause with patients who were alive at the time of the final analysis or who became lost to follow-up censored at their last date known to be alive., 24 months","Progression-free Survival, Defined as the time from randomization to the first objective documentation of disease progression, defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, or death due to any cause with patients who had not progressed or died at the time of final analysis censored on the date of the last tumour assessment., 24 months|Objective Response Rate, Defined as percentage of participants with objective response over all participants randomized. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR., 24 months",,Canadian Cancer Trials Group,AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,180,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CO26,2016-10-12,2018-10-18,2022-06-07,2016-08-17,2021-01-19,2023-12-08,"Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|The Moncton Hospital, Moncton, New Brunswick, E1C 6Z8, Canada|Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, A1B 3V6, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 1V7, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, L4M 6M2, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, K7L 5P9, Canada|London Regional Cancer Program, London, Ontario, N6A 5W9, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, K1H 8L6, Canada|Algoma District Cancer Program, Sault Ste. Marie, Ontario, P6B 0A8, Canada|Odette Cancer Centre, Toronto, Ontario, M4N 3M5, Canada|University Health Network, Toronto, Ontario, M5G 2M9, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, N8W 2X3, Canada|Hopital Charles LeMoyne, Greenfield Park, Quebec, J4V 2H1, Canada|Hopital de la Cite-de-la-Sante, Laval, Quebec, H7M 3L9, Canada|L'Hotel-Dieu de Levis, Levis, Quebec, G6V 3Z1, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, H2L 4M1, Canada|The Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Centre Integre Universitaire De Sante Et De Services, Montreal, Quebec, H4J 1C5, Canada|CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City, Quebec, G1R 2J6, Canada|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, J1H 5N4, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, Quebec, G8Z 3R9, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, S7N 4H4, Canada","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/20/NCT02870920/Prot_001.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/20/NCT02870920/SAP_000.pdf"
